RecruitingNCT07409506

Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease


Sponsor

Hospices Civils de Lyon

Enrollment

312 participants

Start Date

Sep 9, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

In France, approximately 1,200,000 people aged 65 and over suffer from Alzheimer's disease or related disorders, of which Alzheimer's disease (AD) accounts for 70% of cases. This prevalence could double by 2050. The cognitive decline and progression to functional dependence that accompany AD are associated with a decline in quality of life, an increased risk of comorbidities, institutionalization, and mortality, as well as high care costs, placing a burden on the patient, their family and friends, and the healthcare system. Informal care, i.e., care provided by a family member or caregiver, plays an important role in the overall management of major neurocognitive disorders (NCDs) associated with AD at home. In France, the annual cost of informal care for AD was estimated in 2008 at around €14 billion per year, or approximately 50% of the total annual cost of AD. The economic valuation of informal care serves to inform public decision-makers not only about the cost of this resource, but also about its usefulness. The issue of resource allocation (particularly the daily allowance for family caregivers - AJPA in French) at the societal level and the sharing of private (role of caregivers) and public (role of the state and local authorities) responsibilities leads us to question the determinants of this usefulness, particularly the clinical determinants in AD patients at different stages of the disease. The main hypothesis is that informal care varies according to cognitive decline and loss of autonomy, independently or in interaction with the number and type of the patient's comorbidities, their behavioral disorders, and the caregiver's burden.


Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how family caregivers (unpaid people who look after a loved one with Alzheimer's disease) provide support at different stages of the disease, to better understand the demands placed on caregivers as dementia progresses. **You may be eligible if...** - You are a patient aged 60 or older from the Charpennes Hospital who is part of the MEM-AURA research group - You have been diagnosed with probable Alzheimer's disease at any stage - Your MMSE (memory test) score is 26 or below - You are accompanied by a caregiver at the time of enrollment **You may NOT be eligible if...** - You or your caregiver have expressed opposition to participating in the study - You live in a care home or nursing facility - You are under legal guardianship or other legal protection measures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHER" Ressources Utilisation in Dementia " (RUD) questionnaire.

Questionnaire on the use of services available to patients with dementia.


Locations(1)

Hôpital des Charpennes

Villeurbanne, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07409506


Related Trials